Bora Pharmaceuticals today announced that it has completed the acquisition of Upsher-Smith Laboratories, a generics manufacturer and marketer based in Minnesota, US, from its sellers: Sawai Group Holdings and Sumitomo Corporation of Americas.
Upsher-Smith now is a wholly-owned subsidiary of Bora Group.
Bobby Sheng, Chair and CEO of Bora Group, will immediately assume the role of Chair for Upsher-Smith and Rich Fisher, COO & President of Upsher-Smith, will continue to lead operations for the business, reporting directly to Mr Sheng.
Mr Sheng commented: “The acquisition of Upsher-Smith marks a significant milestone in Bora’s growth strategy as we forge ahead with our expansion plans in the US market. It will also support the CDMO strategy to grow our US footprint,”
“The acquisition of Upsher-Smith also complements our existing TWi division, allowing us to expand our reach in the US market by pairing Upsher-Smith’s specialty generics platform with TWi’s current product portfolio and distribution channels.”
Through this acquisition, Bora not only gains additional capacity to support its CDMO business, but also adds to its capability to serve customers throughout the pharmaceutical value chain, covering the entire US market.
